49 studies found for:    "Kennedy disease"
Show Display Options
Rank Status Study
1 Completed
Has Results
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
Conditions: Kennedy's Disease;   Spinal and Bulbar Muscular Atrophy
Interventions: Drug: Dutasteride;   Drug: Placebo
2 Unknown  Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
Conditions: Spinobulbar Muscular Atrophy;   Kennedy's Disease
Interventions: Drug: Goserelin;   Procedure: Electrophysiologic study;   Procedure: tissue biopsy
3 Not yet recruiting High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Spinal and Bulbar Muscular Atrophy;   Healthy Subjects
Interventions: Other: Supervised high intensity training;   Other: Optional training;   Other: Control period;   Other: Unsupervised High intensity training
4 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
5 Recruiting Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Condition: Spinal and Bulbar Muscular Atrophy
Interventions: Drug: BVS857;   Drug: Placebo
6 Completed Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
Conditions: Spinal Muscular Atrophy;   Amyotrophic Lateral Sclerosis;   Spinobulbar Muscular Atrophy
Interventions: Drug: leuprolide;   Drug: testosterone
7 Recruiting Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Intervention: Drug: AZD5312
8 Recruiting Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian;   Recurrent Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Carcinoma.
Intervention: Drug: Enzalutamide
9 Recruiting Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
Conditions: Libido;   Receptors, Androgen;   Polymorphism, Genetic;   Androgen Effect
Intervention:
10 Recruiting Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Liver;   Motor Neuron Disease
Intervention:
11 Withdrawn STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: STA9090;   Drug: STA9090 with Dutasteride
12 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
13 Recruiting The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: LHRH Agonist
14 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
15 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
16 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
17 Recruiting A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Conditions: Pre-treated Postmenopausal Patients With ER/PgR-negative/AR-positive or ER;   and/or PgR-positive/AR-positive Metastatic Breast Cancer
Intervention: Drug: DHEA (Dehydroepiandrosterone)
18 Completed Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Drug: Finasteride
19 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
20 Recruiting A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: JNJ-56021927

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years